Published in Clin Cancer Res on July 21, 2009
Avera/Sema4 Oncology and Analytics Protocol (ASAP) | NCT05142033
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics (2012) 1.63
Population differences in microRNA expression and biological implications. RNA Biol (2011) 1.33
Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery. Pharmacogenomics (2010) 1.12
Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis (2011) 1.10
Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000-2010. BMC Cancer (2013) 1.09
Relating human genetic variation to variation in drug responses. Trends Genet (2012) 1.05
Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial. Jpn J Clin Oncol (2013) 0.94
Evidence for non-communicable diseases: analysis of Cochrane reviews and randomised trials by World Bank classification. BMJ Open (2013) 0.94
Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer (2012) 0.89
The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology. Yonsei Med J (2013) 0.89
Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer (2014) 0.87
Using germline genomics to individualize pediatric cancer treatments. Clin Cancer Res (2012) 0.87
Genome-wide approaches in pharmacogenomics: heritability estimation and pharmacoethnicity as primary challenges. Pharmacogenomics (2012) 0.87
Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials. Int J Clin Oncol (2011) 0.84
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. Br J Cancer (2013) 0.83
Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II? Clin Cancer Res (2012) 0.80
Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review. Mol Clin Oncol (2014) 0.80
Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. J Gastrointest Oncol (2014) 0.80
Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. Pharmacogenomics J (2013) 0.80
Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. Clin Cancer Res (2015) 0.80
Expression of CA125 and cisplatin susceptibility of pleural effusion-derived human lung cancer cells from a Thai patient. Oncol Lett (2012) 0.79
Tumor response and clinical toxicity associated with second-line chemotherapy regimens for advanced non-squamous non-small cell lung cancer: A retrospective cohort study. Thorac Cancer (2014) 0.78
Allele Frequencies of the Epidermal Growth Factor Receptors Polymorphism R521K in Colorectal Cancer Patients and Healthy Subjects Indicate a Risk-Reducing Effect of K521 in Syrian Population. N Am J Med Sci (2013) 0.77
Genomic Disparities in Breast Cancer Among Latinas. Cancer Control (2016) 0.76
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. Cancer Res Treat (2016) 0.75
Pharmacogenetics in Jewish populations. Drug Metabol Drug Interact (2014) 0.75
Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study. Med Oncol (2016) 0.75
Host-Microbe Co-metabolism Dictates Cancer Drug Efficacy in C. elegans. Cell (2017) 0.75
GST M1-T1 null allele frequency patterns in geographically assorted human populations: a phylogenetic approach. PLoS One (2015) 0.75
Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours. Sci Rep (2016) 0.75
Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India. Indian J Med Paediatr Oncol (2017) 0.75
The genetic profiles of CYP1A1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity in Turkish population. Saudi Pharm J (2016) 0.75
Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study. Prostate Int (2015) 0.75
Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer. Oncol Lett (2017) 0.75
Genome Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. Clin Cancer Res (2017) 0.75
Can the chemotherapeutic agents perform anticancer activity though miRNA expression regulation? Proposing a new hypothesis. Protoplasma (2015) 0.75
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet (2008) 30.94
Genetic structure of human populations. Science (2002) 30.91
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
Human genetic variation and its contribution to complex traits. Nat Rev Genet (2009) 12.11
The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med (2003) 7.94
Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet (2004) 4.51
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer (2006) 3.92
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol (2008) 3.53
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet (2007) 3.05
Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol (2005) 3.02
Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol (2001) 2.86
Cytochrome P450 pharmacogenetics and cancer. Oncogene (2006) 2.38
Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int (1997) 2.25
Comparison of three methods to estimate genetic ancestry and control for stratification in genetic association studies among admixed populations. Hum Genet (2005) 2.19
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther (2007) 2.05
Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol (1997) 2.02
Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol (2006) 1.93
Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet (2001) 1.91
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics (2007) 1.84
The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther (2008) 1.75
Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther (2008) 1.74
Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res (1993) 1.73
Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res (2007) 1.73
Genome-wide association studies: implications for multiethnic samples. Hum Mol Genet (2008) 1.69
Assessing genetic contributions to phenotypic differences among 'racial' and 'ethnic' groups. Nat Genet (2004) 1.62
Individual genomes instead of race for personalized medicine. Clin Pharmacol Ther (2008) 1.56
Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood (2007) 1.52
Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res (2004) 1.51
Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol (2006) 1.49
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood (2008) 1.46
Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin (2009) 1.39
Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst (2002) 1.38
Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol (2003) 1.38
Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res (2003) 1.37
Changing the paradigm from 'race' to human genome variation. Nat Genet (2004) 1.37
Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics (1999) 1.34
Doxorubicin cardiotoxicity in African Americans. J Natl Med Assoc (2004) 1.32
Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet (2000) 1.29
Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer (2001) 1.29
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol (2005) 1.23
Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer (2007) 1.21
Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer (2008) 1.18
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther (2006) 1.18
Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res (1998) 1.16
Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther (2008) 1.14
Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics (2007) 1.09
Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells. Cancer Res (2004) 1.09
A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol (2006) 1.08
Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol (1997) 1.08
Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics (2008) 1.05
Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat (2000) 1.03
Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther (2005) 1.00
Interpreting P values in pharmacogenetic studies: a call for process and perspective. J Clin Oncol (2007) 0.99
Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med (2005) 0.99
Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics (2007) 0.99
Barriers to cancer clinical trial participation among Native elders. Ethn Dis (2008) 0.98
Pharmacogenetics in cancer treatment. Annu Rev Med (2001) 0.95
Pharmacogenetics and cancer chemotherapy. Eur J Cancer (1998) 0.92
The oral fluorinated pyrimidines. Invest New Drugs (2001) 0.92
Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients. Anticancer Drugs (2003) 0.87
A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer. Oncol Rep (2003) 0.84
A feasibility study of paclitaxel 225 mg/m(2) and carboplatin AUC = 6 in untreated advanced non-small cell lung cancer patients in Japan. Jpn J Clin Oncol (2002) 0.80
Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet (2010) 10.75
SCAN: SNP and copy number annotation. Bioinformatics (2009) 5.96
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet (2008) 4.01
Genetic architecture of transcript-level variation in humans. Am J Hum Genet (2008) 3.36
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet (2007) 3.05
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol (2009) 2.47
Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A (2010) 2.43
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther (2007) 2.05
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Identification of common genetic variants that account for transcript isoform variation between human populations. Hum Genet (2008) 1.96
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res (2007) 1.73
The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics. Bioinform Biol Insights (2008) 1.73
Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther (2008) 1.67
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol (2005) 1.63
Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics (2012) 1.63
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res (2005) 1.62
Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA (2005) 1.59
Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res (2008) 1.57
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol (2002) 1.50
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood (2008) 1.46
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun (2013) 1.43
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet (2012) 1.41
SNPinProbe_1.0: a database for filtering out probes in the Affymetrix GeneChip human exon 1.0 ST array potentially affected by SNPs. Bioinformation (2008) 1.41
Population differences in microRNA expression and biological implications. RNA Biol (2011) 1.33
Genome-wide variation of cytosine modifications between European and African populations and the implications for complex traits. Genetics (2013) 1.31
Exprtarget: an integrative approach to predicting human microRNA targets. PLoS One (2010) 1.31
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol (2007) 1.31
Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet (2008) 1.26
Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death. Proc Natl Acad Sci U S A (2012) 1.26
Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics (2008) 1.26
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
Variants affecting exon skipping contribute to complex traits. PLoS Genet (2012) 1.24
Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev (2006) 1.23
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther (2005) 1.23
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res (2011) 1.22
Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects. Curr Bioinform (2008) 1.19
Integrating Epigenomics into Pharmacogenomic Studies. Pharmgenomics Pers Med (2008) 1.18
Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics (2005) 1.13
Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery. Pharmacogenomics (2010) 1.12
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther (2009) 1.11
Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet (2012) 1.08
Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes. RNA Biol (2009) 1.07
Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans. Pharmacogenet Genomics (2008) 1.06
Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J Pharmacol Exp Ther (2008) 1.06
On the challenges of the HapMap resource. Bioinformation (2008) 1.06
Relating human genetic variation to variation in drug responses. Trends Genet (2012) 1.05
Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics (2009) 1.04
O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther (2002) 1.04
Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res (2012) 1.03
Population differences in the rate of proliferation of international HapMap cell lines. Am J Hum Genet (2010) 1.00
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther (2011) 1.00
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs (2008) 0.99
Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab (2011) 0.99
Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics (2007) 0.99
Gene set enrichment analyses revealed differences in gene expression patterns between males and females. In Silico Biol (2009) 0.99
Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One (2011) 0.99
Genetics and variable drug response. JAMA (2011) 0.96
Population-specific GSTM1 copy number variation. Hum Mol Genet (2008) 0.96
Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes? Pharmacogenomics (2013) 0.95
Role of GADD34 in modulation of cisplatin cytotoxicity. Biochem Pharmacol (2005) 0.95
Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding. Cancer Res (2007) 0.95
Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin Cancer Res (2002) 0.94
Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet Genomics (2012) 0.94
Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des (2009) 0.93
Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol (2011) 0.93
Comprehensive survey of SNPs in the Affymetrix exon array using the 1000 Genomes dataset. PLoS One (2010) 0.92
Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics (2009) 0.92
A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol (2006) 0.91
Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis (2006) 0.91
Poly-omic prediction of complex traits: OmicKriging. Genet Epidemiol (2014) 0.91
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Mol Cancer Ther (2004) 0.90
Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity. J Pharmacol Exp Ther (2004) 0.89
Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer (2012) 0.89
Expression and alternative splicing of folate pathway genes in HapMap lymphoblastoid cell lines. Pharmacogenomics (2009) 0.89
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol (2007) 0.89
Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals. DNA Repair (Amst) (2007) 0.88
Temozolomide: realizing the promise and potential. Curr Opin Oncol (2003) 0.88
A pharmacogene database enhanced by the 1000 Genomes Project. Pharmacogenet Genomics (2009) 0.88
Ancestry-related differences in gene expression: findings may enhance understanding of health disparities between populations. Pharmacogenomics (2008) 0.87
Using germline genomics to individualize pediatric cancer treatments. Clin Cancer Res (2012) 0.87
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity. Trends Cancer Res (2008) 0.87
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood (2013) 0.87
Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins. Clin Cancer Res (2011) 0.86
Characterization of multiple promoters in the human carboxylesterase 2 gene. Pharmacogenetics (2003) 0.86
Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Mol Cancer Ther (2003) 0.86
Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine. Cancer Chemother Pharmacol (2004) 0.85
Integrative genomics: quantifying significance of phenotype-genotype relationships from multiple sources of high-throughput data. Front Genet (2013) 0.85
The emerging role of microRNAs in drug responses. Curr Opin Mol Ther (2010) 0.85
Allelic loss at the GPx-1 locus in cancer of the head and neck. Biol Trace Elem Res (2004) 0.85
Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol (2008) 0.84
Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet (2013) 0.84
The use of genomic information to optimize cancer chemotherapy. Semin Oncol (2011) 0.84
Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. J Natl Cancer Inst (2012) 0.84
Cell cycle arrest in a model of colistin nephrotoxicity. Physiol Genomics (2013) 0.84
Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. Pharmacogenetics (2004) 0.83